Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
Completed · Phase 2
Conditions studied: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer
In brief
This phase II trial is studying how well bortezomib followed by doxorubicin at the time of disease progression works in treating patients with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (cancer) of the head and neck. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining bortezomib with doxorubicin may kill more tumor cells
Key facts
- Study ID
- NCT00077428
- Run by
- National Cancer Institute (NCI)
- People needed
- 37
- Starts
- 2004-06-01
- Last updated by the study team
- 2013-01-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed adenoid cystic carcinoma of the head and neck
- Locally advanced, recurrent, or metastatic disease that is considered incurable by known therapies
- Unidimensionally measurable disease
- Must not have stable disease for at least 9 months before study entry
- No known brain metastases
- Performance status - ECOG 0-2
- Absolute neutrophil count at least 1,500/mm\^3
- Platelet count at least 100,000/mm\^3
- AST and ALT no greater than 2.5 times upper limit of normal
- Bilirubin normal
- Creatinine normal
- Creatinine clearance at least 60 mL/min
- LVEF at least lower limit of normal by MUGA
- No history of congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No active or ongoing infection
- No prior allergy to compounds of similar chemical or biological composition to bortezomib
- No other concurrent uncontrolled illness
- No psychiatric illness or social situation that would preclude study compliance
- No pre-existing neuropathy > grade 1
Where it is running
- Eastern Cooperative Oncology Group — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.